核苷（酸）类药物治疗HBeAg阳性CHB患者血清HBsAg水平变化Meta分析*

doi:10.3969/j.issn.1672-5069.2018.02.009

摘要/Abstract

摘要： 目的系统评价HBeAg阳性慢性乙型肝炎（CHB）患者在接受核苷（酸）类药物(NAs)治疗过程中HBsAg的动态变化对血清学转换的预测价值。方法检索PubMed、EMBASE、Cochrane Central Register数据库中关于HBsAg水平与HBeAg阳性的CHB患者在接受NAs治疗过程中发生血清学转换关系的临床研究。应用RevMan 5.2 软件。结果研究共纳入10篇文献,包括467例CHB患者。HBeAg阳性患者发生HBsAg应答组HBeAg血清学转换率为64.3%,显著高于未发生HBsAg应答组的19.8%（P<0.0001）;HBsAg应答组HBsAg消失率为30.5%,显著高于未发生HBsAg应答组的0.4%（P<0.05）;发生HBeAg血清学转换患者HBsAg基线水平为（3.4±0.6） lg IU/mL,与未发生HBeAg血清学转换患者的（3.7±0.4） lg IU/mL比,无显著差异（P>0.05）。结论 HBeAg阳性患者在NAs抗病毒治疗过程中,HBsAg早期快速下降是患者发生HBeAg血清学转换的有效预测因素,甚至对HBsAg的消失也有一定的预测作用。

关键词: 慢性乙型肝炎, 核苷（酸）类似物, HBsAg, HBeAg血清学转换, Meta分析

Abstract: Objective To perform a systematic review on the predictive value of serum HBsAg levels in patients with HBeAg positive chronic hepatitis B（CHB） treated with nucleos（t）ide analogues（NAs）. Methods A systematic search was performed on clinical trials regarding quantitative detection of serum HBsAg before and after antiviral treatment with NAs in patients with HBeAg positive CHB in PubMed,EMBASE and Cochrane Central Register between January 1,2006 and August 1,2016. Data was extracted by two reviewers independently. Statistical analysis was performed by using RevMan 5.2. HBsAg response was defined as serum HBsAg levels declined more than 1 lg IU/mL from baseline levels within 1 year after treatment with NAs. The other observation indexes were baseline HBsAg levels,HBeAg seroconversion and HBsAg loss. Results 10 eligible studies（467 patients in total） were enrolled in this Meta-analysis. The rate of HBeAg seroconversion in patients with HBsAg response was 64.3%,significantly higher than 19.8% in patients without HBsAg response（P<0.0001）;the rate of HBsAg loss in patients with HBsAg response was 30.5%,also significantly higher than 0.4% in patients without HBsAg response（P<0.05）;the baseline HBsAg levels were not shown different between patients with,（3.4±0.6 lg IU/mL） and paitents without HBeAg seroconversion（3.7±0.4 lg IU/mL,P﹥0.05）. Conclusions During the treatment with NAs,a rapid decline of serum HBsAg levels might predict serological response in HBeAg positive CHB patients.

Key words: Hepatitis B, Nucleos（t）ide analogs, HBsAg, HBeAg seroconversion, Meta-analysis

张海月, 王鲁文, 刘菲菲, 龚作炯. 核苷（酸）类药物治疗HBeAg阳性CHB患者血清HBsAg水平变化Meta分析*[J]. 实用肝脏病杂志, 2018, 21(2): 191-195.

Zhang Haiyue, Wang Luwen, Liu Feifei, et al. Serum HBsAg levels in prognosis of serological response to nucleos（t）ide analog therapy in patients with HBeAg positive chronic hepatitis B:a Meta-analysis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 191-195.

参考文献

[1] Chang TT,Gish RG,de Man R,et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med,2006,354:1001-1010.
[2] Lai CL,Shouval D,Lok AS,et al.Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med,2006,354:1011-1020.
[3] Heathcote EJ,Marcellin P,Buti M,et al.Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology,2011,140:132-143.
[4] Marcellin P,Heathcote EJ,Buti M,et al.Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med,2008,359:2442-2455.
[5] Thompson AJ,Nguyen T,Iser D,et al.Serum hepatitis B surface antigen and hepatitis B e antigen titers:disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology,2010,51:1933-1944.
[6] Nguyen T,Desmond P,Locarnini S.The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B. Hepatol Int,2009,3:5-15.
[7] Raimondo G,Brunetto MR,Pontisso P,et al.Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology,2006,43:100-107.
[8] Werle-Lapostolle B,Bowden S,Locarnini S,et al.Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology,2004,126:1750-1758.
[9] Pichoud C,Berby F,Stuyver L.Persistence of viral replication after anti-HBe seroconversion during antiviral therapy for chronic hepatitis B. J Hepatol,2000,32:307-316.
[10] Janssen HL,van Zonneveld M,Senturk H,et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B:a randomised trial. Lancet,2005,365:123-129.
[11] Lau GK,Piratvisuth T,Luo KX,et al.Peginterferon alfa-2a HBeAg-positive chronic hepatitis B study group. Peginterferon alfa-2a,lamivudine,and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med,2005,352:2682-2695.
[12] Gish RG,Lau DT,Schmid P,et al.A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B. Am J Gastroenterol,2007,102:2718-2723.
[13] Manesis EK,Hadziyannis ES,Angelopoulou OP,et al.Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B:a clue from serum HBsAg levels. Antivir Ther,2007,12:73-82.
[14] Lee JM,Ahn SH,Kim HS,et al.Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology,2011,53:1486-1493.
[15] Tseng TC,Kao JH.Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B:new trick of old dog. J Gastroenterol,2013,48(1):13-21.
[16] Lee MH,Lee da M,Kim SS,et al. Correlation of serum hepatitis B surface antigen level with response to entecavir in naive patients with chronic hepatitis B. J Med Virol,2011,83:1178-1186.
[17] Jung YK,Kim JH,Lee YS,et al.Change in serum hepatitis B surface antigen level and its clinical significance in treatment-naive, hepatitis Be antigen-positive patients receiving entecavir. J Clin Gastroenterol,2010,44(9):653-657.
[18] Reijnders JG,Rijckborst V,Sonneveld MJ,et al.Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol,2011,54:449-454.
[19] Carey I,Bruce M,Horner M,et al.HBsAg plasma level kinetics: a new role for an old marker as a therapy response predictor in vertically infected children on combination therapy. J Viral Hepat,2015,22:441-452.
[20] Wursthorn K,Jung M,Riva A,et al.Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology,2010,52:1611-1620.
[21] Cai W,Xie Q,An B,et al.On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients. J Clin Virol,2010,48:22-26.
[22] Wiegand J,Wedemeyer H,Finger A,et al.A decline in hepatitis B virus surface antigen(HBsAg) predicts clearance,but does not correlate with quantitative HBeAg or HBV DNA levels. Antivir Ther,2008,13:547-554.
[23] Wang CC,Tseng TC,Wang PC,et al.Baseline hepatitis B surface antigen quantitation can predict virologic response in entecavir-treated chronic hepatitis B patients. J Formos Med Assoc,2014,113:786-793.
[24] Kim SS,Lee D,Lee MH,et al.Association of on-treatment serum hepatitis B surface antigen level with sustained virological response to nucleos(t)ide analog in patients with hepatitis B e-antigen positive chronic hepatitis B. Hepatol Res,2013,43:219-227.
[25] Yang J,Chen J,Ye P,et al.HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients. J Transl Med,2014,12:183.
[26] Marcellin P,Gane E,Buti M,et al.Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B:a 5-year open-label follow-up study. Lancet,2013,381:468-475.
[27] Chang TT,Liaw YF,Wu SS,et al.Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology,2010,52:886-893.
[28] Papatheodoridis GV,Lampertico P,Manolakopoulos S,et al.Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy:a systematic review. J Hepatol,2010,53:348-356.
[29] Hosaka T,Suzuki F,Kobayashi M,et al.Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology,2013,58:98-107.
[30] Chen YC,Sheen IS,Chu CM,et al.Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology,2002,123:1084-1089.
[31] Yuen MF,Wong DK,Sablon E,et al.HBsAg seroclearance in chronic hepatitis B in the Chinese:virological,histological,and clinical aspects. Hepatology,2004,39:1694-1701.
[32] Moucari R,Mackiewicz V,Lada O,et al.Early serum HBsAg drop:a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology,2009,49:1151-1157.
[33] Manesis EK,Papatheodoridis GV,Tiniakos DG,et al.Hepatitis B surface antigen:relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B. J Hepatol,2011,55:61-68.
[34] Sonneveld MJ,Rijckborst V,Boucher CA,et al.Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology,2010,52:1251-1257.
[35] Jaroszewicz J,Ho H,Markova A,et al.Hepatitis B surface antigen(HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues. Antivir Ther,2011,16:915-924.
[36] Brunetto MR,Moriconi F,Bonino F,et al.Hepatitis B virus surface antigen levels:a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology,2009,49:1141-1150.
[37] Wang J,Du LY,Zhu X,et al.The predictive value of early indicators for HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with Telbivudine treatment for 104 weeks. Indian J Med Microbiol,2015,33(Suppl 1):20-25.
[38] Shin JW,Jung SW,Park BR,et al.Prediction of response to entecavir therapy in patients with HBeAgpositive chronic hepatitis B based on on-treatment HBsAg,HBeAg and HBV DNA levels. J Viral Hepat,2012,19:724-731.